Kilitch Drugs (India) Limited has scheduled its 34th Annual General Meeting (AGM) for Thursday, August 27, 2026, at 9:00 a.m., to be conducted via Video Conferencing or Other Audio Visual Means (VC/OAVM). This remote format ensures accessibility for shareholders while adhering to regulatory guidelines for corporate governance. The company will close its Register of Members and Share Transfer Books from Thursday, August 20, 2026, through Thursday, August 27, 2026, both days inclusive, to determine shareholder eligibility for voting rights and notice receipt.

The remote e-voting facility will commence on Monday, August 24, 2026, at 9:00 a.m. IST and conclude on Wednesday, August 26, 2026, at 5:00 p.m. IST. Only shareholders whose names appear in the Register of Members or Register of Beneficial Owners as of the cut-off date, Thursday, August 20, 2026, are entitled to vote. The cut-off date for determining eligibility to receive the Notice of AGM was Friday, July 24, 2026.

Voting Mechanism and Compliance

In compliance with Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, the Secretarial Standard on General Meetings (SS-2), and Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Kilitch Drugs is providing remote e-voting facilities. The company has appointed MUFG Intime India Private Limited as its Share Transfer Agent to facilitate electronic voting.

Shareholders who have already cast their votes via remote e-voting may attend the AGM but cannot vote again during the meeting. Attendance via VC/OAVM counts toward quorum under Section 103 of the Companies Act, 2013.

Key Dates and Details

The Annual Report for FY25-26 and the Notice of AGM were dispatched electronically on Saturday, August 1, 2026, to members with registered email addresses. Physical intimations containing web links were sent to shareholders without registered emails, as per Ministry of Corporate Affairs and SEBI circulars. The documents are available on the company’s website and stock exchange portals.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE729D01010/03f71d7895fd4b60.pdf

Kilitch Drugs (India) Limited reported a consolidated net profit of ₹32.39.96 lakh for the fiscal year ended March 31, 2026 (FY26), an increase from ₹31.15.69 lakh in FY25, driven by robust export sales and improved operational efficiencies. The pharmaceutical manufacturer has scheduled its 34th Annual General Meeting (AGM) for August 27, 2026, to seek shareholder approval for performance-linked incentives totaling ₹2 crore for its executive directors and to ratify the remuneration of its cost auditors.

The Board of Directors approved these resolutions during a meeting held on July 28, 2026, in compliance with Regulation 30 and Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has closed its Register of Members and Share Transfer Books from August 20, 2026, to August 27, 2026, both days inclusive, to determine shareholders entitled to vote. This closure is mandated under Regulation 42 of the SEBI Listing Regulations.

Key Financial Performance

Kilitch Drugs achieved a consolidated revenue from operations of ₹23,547.49 lakh in FY26, compared to ₹19,831.85 lakh in the previous year. The growth was primarily fueled by export sales, which stood at ₹13,281.46 lakh, representing a significant portion of the total income. Standalone revenue from operations also rose to ₹18,857.43 lakh from ₹18,158.73 lakh.

The company’s EBITDA for the consolidated entity was ₹4,628.47 lakh. Management highlighted that the new greenfield manufacturing facility at Pen, Maharashtra, is now operational in phases, strengthening manufacturing capabilities and supply chain resilience.

Executive Compensation and AGM Agenda

The primary special business involves approving Performance-Linked Incentives (PLI) for three executive directors, based on the recommendation of the Nomination and Remuneration Committee. The Board cited their pivotal role in business growth and brand development as justification for the payouts.

Additionally, shareholders will ratify the remuneration of M/s Arvind Kumar & Co., Cost Accountants (Firm Registration No. 000646), for the financial year 2026-27. The approved fee is ₹60,000 excluding taxes. The firm’s partner, Mr. Arvind Kumar (Membership No. 37904), has no relationship with the company’s directors or key managerial personnel.

Voting and Compliance Details

The remote e-voting facility will be active from Monday, August 24, 2026, at 9:00 am IST, until Wednesday, August 26, 2026, at 5:00 pm IST. Only members recorded in the Register of Members or Register of Beneficial Owners as of the cut-off date, August 20, 2026, are eligible to vote. Mr. Deep Shukla of Deep Shukla & Associates, Company Secretaries, has been appointed as the Scrutinizer to oversee the voting process and declare results within 48 hours of the meeting's conclusion.

Shareholders attending via video conferencing must register through the InstaMeet platform. Those who have already cast remote e-votes may attend but cannot vote again during the live session. The company emphasizes that all transfers of physical securities must be in demat mode, as per SEBI circulars effective from January 25, 2022.